Lorna Charles

825 total citations · 1 hit paper
34 papers, 557 citations indexed

About

Lorna Charles is a scholar working on Genetics, Surgery and Hepatology. According to data from OpenAlex, Lorna Charles has authored 34 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 11 papers in Surgery and 9 papers in Hepatology. Recurrent topics in Lorna Charles's work include Inflammatory Bowel Disease (16 papers), Liver Diseases and Immunity (9 papers) and Eosinophilic Esophagitis (6 papers). Lorna Charles is often cited by papers focused on Inflammatory Bowel Disease (16 papers), Liver Diseases and Immunity (9 papers) and Eosinophilic Esophagitis (6 papers). Lorna Charles collaborates with scholars based in United States, Italy and Netherlands. Lorna Charles's co-authors include Subrata Ghosh, Douglas C. Wolf, AnnKatrin Petersen, Keith Usiskin, Geert D’Haens, Stephen B. Hanauer, William J. Sandborn, Brian G. Feagan, Silvio Danese and Igor Jovanović and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Lorna Charles

26 papers receiving 537 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

2021 335 citations William J. Sandborn, Brian G. Feagan et al. profile →

Peers

Lorna Charles

GENET

EPIDE

IMMUN

SURGE

Willem-Jan Wollants Belgium

Torao Tanaka Japan

Simon Hirschmann Germany

Veerle J. Nuij Netherlands

Martina Goetsch United States

Stine Roug Denmark

Shaista Rashid Denmark

John Beckly United Kingdom

Javaid Subhani United Kingdom

Lorenzo Oliva Italy

Willem-Jan Wollants Belgium

Lorna Charles

287 ×0.7

GENET

167 ×0.7

EPIDE

144 ×1.1

IMMUN

85 ×0.7

80 ×0.7

SURGE

Citations per year, relative to Lorna Charles Lorna Charles (= 1×) peers Willem-Jan Wollants

Countries citing papers authored by Lorna Charles

Since Specialization

Citations

This map shows the geographic impact of Lorna Charles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorna Charles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorna Charles more than expected).

Fields of papers citing papers by Lorna Charles

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorna Charles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorna Charles. The network helps show where Lorna Charles may publish in the future.

Co-authorship network of co-authors of Lorna Charles

This figure shows the co-authorship network connecting the top 25 collaborators of Lorna Charles. A scholar is included among the top collaborators of Lorna Charles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lorna Charles. Lorna Charles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

D’Haens, Geert, Marc Ferrante, Katsuyoshi Matsuoka, et al.. (2024). P98 Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the true north open-label extension study. Poster presentations. A109–A110.

Regueiro, Miguel, Britta Siegmund, Sara N. Horst, et al.. (2024). Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis. Inflammatory Bowel Diseases. 31(4). 1010–1017.

Siegel, Corey A., David T. Rubin, Millie D. Long, et al.. (2024). Su1771 SAFETY OF LONG-TERM OZANIMOD TREATMENT FOR UP TO 4 YEARS BY AGE GROUP IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION. Gastroenterology. 166(5). S–805.

D’Haens, Geert, Bruce E. Sands, Marc Ferrante, et al.. (2024). P1009 Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study. Journal of Crohn s and Colitis. 18(Supplement_1). i1814–i1815.

Danese, Silvio, et al.. (2023). P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension. Journal of Crohn s and Colitis. 17(Supplement_1). i534–i535. 3 indexed citations

Danese, Silvio, Remo Panaccione, María T. Abreu, et al.. (2023). Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. Journal of Crohn s and Colitis. 18(2). 264–274. 26 indexed citations

Danese, Silvio, et al.. (2023). DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study. Journal of Crohn s and Colitis. 17(Supplement_1). i101–i102. 4 indexed citations

Charles, Lorna, Vikram Kate, Sandhiya Selvarajan, et al.. (2023). Clinicopathological features and survival outcomes for gastric adenocarcinoma: Real-world single-center data. Indian Journal of Gastroenterology. 43(6). 1209–1219.

Armuzzi, Alessandro, Gary R. Lichtenstein, Jason K. Hou, et al.. (2023). Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses. Clinical Gastroenterology and Hepatology. 22(5). 1067–1076.e3. 13 indexed citations

10.

Abreu, María T., Silvio Danese, Douglas C. Wolf, et al.. (2023). 950 LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION. Gastroenterology. 164(6). S–208. 1 indexed citations

11.

Dubashi, Biswajit, Lorna Charles, Rajesh Nachiappa Ganesh, et al.. (2023). Immunohistochemistry-based molecular classification of gastric cancer in India: How are we different?. Journal of Clinical Oncology. 41(4_suppl). 462–462.

12.

Dubashi, Biswajit, Zachariah Bobby, Jaya Prakash Sahoo, et al.. (2023). Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy. Journal of Bone and Mineral Metabolism. 41(5). 682–692. 2 indexed citations

13.

Dubinsky, Marla C., Lorna Charles, Krzysztof Selmaj, et al.. (2023). S1161 Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn’s Disease, and Relapsing Multiple Sclerosis. The American Journal of Gastroenterology. 118(10S). S888–S888. 1 indexed citations

14.

Siegmund, Britta, Silvio Danese, J.F. Colombel, et al.. (2022). Long-term use of ozanimod in patients with moderately to severely active ulcerative colitis. Zeitschrift für Gastroenterologie. 60(8). e428–e428. 2 indexed citations

15.

Danese, Silvio, Jean‐Frédéric Colombel, Terry Ponich, et al.. (2022). DOP44 Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis. Journal of Crohn s and Colitis. 16(Supplement_1). i093–i094. 4 indexed citations

16.

Wolf, Douglas C., Jean Frédéric Colombel, Terry Ponich, et al.. (2022). Tu1458: LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS. Gastroenterology. 162(7). S–969. 3 indexed citations

17.

Cross, Raymond K., Jonathan Calkwood, Ashwini Pai, et al.. (2021). P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis. The American Journal of Gastroenterology. 116(1). S9–S10. 6 indexed citations

18.

Sandborn, William J., Brian G. Feagan, Stephen B. Hanauer, et al.. (2021). Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. Journal of Crohn s and Colitis. 15(7). 1120–1129. 82 indexed citations

19.

Colombel, Jean‐Frédéric, Geert D’Haens, Peter M. Irving, et al.. (2021). P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial. The American Journal of Gastroenterology. 116(1). S9–S9. 5 indexed citations

20.

Charles, Lorna, et al.. (1970). Pre-Hospital Management of Acute Myocardial Infarction. 6(3). 139–142. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact